Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Finviz2026/03/02 15:51

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rallybio Corporation (NASDAQ:RLYB) shares are up Monday following a merger agreement with Candid Therapeutics Inc.

This news has generated excitement among investors as the combined company aims to advance a leading portfolio of T-cell engager therapeutics for autoimmune diseases, adding momentum to the stock’s performance.

Merger

The merger will see Rallybio acquire Candid, which has secured over $505 million in financing from a syndicate of leading healthcare institutional investors. Pro-forma cash of approximately $700 million is expected to provide the combined company with a strong financial foundation.

The funding is expected to support operations through 2030, allowing the combined entity to push forward with multiple clinical milestones, including Phase 2 studies for its T-cell engager programs.

The transaction is anticipated to close in mid-2026, pending stockholder approval and regulatory conditions.

Following the merger, Rallybio equityholders are expected to own approximately 3.65% of the combined company, while Candid equityholders will hold around 96.35%.

Upon completion of the merger, the combined company expects to operate under the name Candid Therapeutics and trade on Nasdaq under the ticker symbol “CDRX”.

The broader market experienced declines on the previous trading day, with the Nasdaq down 1.40% and the S&P 500 falling 1.07%. This backdrop suggests that Rallybio’s gains are driven by company-specific news rather than broader market trends, as most sectors faced downward pressure.

RLYB Price Action: Rallybio shares were up 29.05% at $9.73 at the time of publication on Monday. The stock is trading at a new 52-week high.

Photo via Shutterstock

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.

Bitget•2026/11/02 08:28